Skip to main content
Skip to main content
Home
Company
About Us
Executive Team
Board of Directors
Scientific & Clinical Advisors
Partners
Pipeline
Technology
EQ504
EQ302
Publications
Presentations
Investors
Investor Overview
Stock Information
Stock Chart
Analyst Coverage
Press Releases
Events & Presentations
Email Alerts & Contacts
SEC Filings
Corporate Governance
Governance Documents
Committee Composition
Investor FAQs
Careers
Contact Us
Search query
Our Company
About Us
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and a product platform targeting immuno-inflammatory pathways.
Our Executive Team
We have the privilege to work as a team towards fulfillment of our mission to pioneer new innovations to treat autoimmune and inflammatory diseases and most importantly to make a difference in the lives of patients.
Our Board of Directors
Scientific and Clinical Advisors
